Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 195.00
Bid: 190.00
Ask: 200.00
Change: -43.00 (-18.07%)
Spread: 10.00 (5.263%)
Open: 238.00
High: 238.00
Low: 195.00
Prev. Close: 238.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

Mon, 04th Mar 2024 19:59

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Beowulf Mining PLC - London-based mining company with projects in Sweden, Finland and Kosovo - Announces terms of previously announced fundraise. Says rights issue of Swedish depository receipts will raise up to GBP6.3 million, while a retail offer of ordinary shares in the UK will raise around GBP1.6 million. Notes the SDRs will be offered at SEK0.08 each and the shares at 0.61 pence each. Adds the SDRs will also be offered for subscription, without preferential rights, to institutional investors, other professional investors and the general public in Sweden. Beowulf says it has has received underwriting commitments for the rights issue for around 60% of the total. Explains proceeds will be used mainly to finance the continued development of the Kallak iron ore project in northern Sweden, including completion of the ongoing pre-feasibility study and environmental studies. Funds will also repay amounts advanced under the bridge loan financing arrangements, and corporate costs.

----------

Kefi Gold & Copper PLC - exploration and development company focused on gold and copper projects in the Arabian-Nubian Shield - Plans to raise GBP4.5 million placing at 0.6 pence per share. Further, issues 83.3 million shares to cover accrued fees to certain directors and advisers. In addition, launches retail offer at the same issue price. Explains funds will underpin the launch of the Tulu Kapi Gold project by mid-2024.

----------

LungLife AI Inc - California-based developer of clinical diagnostic solutions for early lung cancer detection - Plans to raise around GBP1.8 million via a GBP1.56 million placing at 35 pence each and a GBP250,000 subscription at the same price. Explains net proceeds, along with existing cash resources, are expected to be utilised to establish the commercial proof of concept of the company's LungLB test. Notes funding is expected to provide the company with a cash runway to early April 2025.

----------

RC365 Holding PLC - London-based company focusing on payment gateway solutions and IT support services - Enters into an unsecured convertible loan note with Mill End Capital Ltd for up to GBP4 million. Says net proceeds of the unsecured loan will be used for the continuing development of existing operations with a particular focus on expanding operations in Malaysia, Japan and the UK. States the first tranche of the CLN comprises GBP600,000, the second tranche a further GBP1.4 million. Any further tranche shall be at the written request of RC365 and discretion of the lender, but will not exceed GBP4 million, RC365 says.

----------

Faron Pharmaceuticals Ltd - Turku-Finland-based clinical-stage biopharmaceutical company - Announces binding commitments worth GBP3.2 million for convertible loans obtained from certain existing shareholders. Explains this allows it to make critical payments to third parties under agreed waivers with IPF. Says this secures its short-term financing needs until the end of March. Faron says talks continue to secure its short and longer-term financing needs, including first additional bridge financing of around EUR5 million. In addition to the short-term bridge financing, Faron intends to propose to the Annual General Meeting an authorization for a larger share issue. In total, Faron expects to need EUR35 million of financing to complete the enrolment of the phase 2 of the BEXMAB study and to obtain regulatory feedback from the US Food & Drug Administration. At February 19, notes cash and cash equivalents held by Faron totalled EUR4.3 million.

----------

Supernova Digital Assets PLC - looks to identify investment and business building opportunities in the Solana and crypto currency ecosystem - Plans return to shareholders. Intends to achieve this by purchasing its own shares through a tender offer. Further, raises GBP242,000 via placing at 0.1 pence per share.

----------

Celsius Resources Ltd - explorer focused on portfolio of copper-gold resources in the Philippines - Advises that trading will be halted on the Australian Securities Exchange effective from March 5 further to the company's request. Celsius says it requested the suspension ahead of an announcement in relation to its flagship Maalinao-Caigutan-Biyog copper-gold project and the issuance of project sensitive documents by the Philippine National Government. Says trading on the AIM market of the London Stock Exchange remains unaffected.

----------

Kibo Energy PLC - Galway, Ireland-based company with energy projects in Africa and the UK - Sells shares in its subsidiary Mast Energy Developments PLC worth GBP29,350. Notes proceeds will be used to pay down the balance balance on the bridge loan facility with RiverFort Global Opportunities PCC Ltd. Holds 33% stake in MED following the share sale.

----------

Braveheart Investment Group PLC - Dodworth, England-based investment company - Provides update on one of its investments, Paraytec Ltd. Notes Paraytec develops high performance specialist detectors for the analytical and life sciences instrumentation markets. In December, Braveheart sought a buyer for Paraytec, of which it owns 100%. But, notes it has been unable to secure an attractive offer and therefore decides to retain Paraytec within its portfolio.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
26 Jun 2019 11:52

Faron Pharmaceuticals Says Traumakine Study Hindered By Steroid Use

(Alliance News) - Faron Pharmaceuticals Oy on Wednesday said interim results from its phase two Inforaaa study support continuation but the study is limited by a lack of patients not also taking a

Read more
14 Jun 2019 11:54

Faron Pharmaceuticals' Analysis Explains "Disappointing" Prior Trial

(Alliance News) - Faron Pharmaceuticals Oy on Friday said analysis of a more recent trial of Traumakine has explained why the drug did not perform as expected in a previous trial.Shares in

Read more
14 Jun 2019 10:37

Faron Pharmaceuticals reports 'significant' findings from YODA study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced results from its pharmacokinetic/dynamic 'YODA' study examining the administration of concomitant steroids and Traumakine in healthy volunteers on Friday.

Read more
24 May 2019 13:34

Faron Pharma Finance Head Wichmann Steps Down, Hanninen Replaces

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Friday said it has made several managerial changes, which it believes will strengthen its operating performance.The clinical stage said

Read more
24 May 2019 11:50

Faron appoints new CFO after some internal shuffling

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, announcing that Yrjö Wichmann was leaving his current role as its chief financial officer to take up the new position of vice-president, financing and investor relations.

Read more
14 May 2019 14:16

Faron Pharmaceuticals Raises EUR1.3 Million Via Share Subscription (ALLISS)

LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The company has issued 1.8 million shares

Read more
7 May 2019 11:44

Faron Pharmaceuticals Narrows Loss On Reduced Clinical Trial Costs

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development costs fell.Faron is a clinical

Read more
2 May 2019 17:30

Faron Pharmaceuticals Knows Of No Reason For 43% Share Price Jump

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursday's 43% share price rise, and said

Read more
30 Apr 2019 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 1 May J SainsburyFull Year ResultsConnect GroupHalf Year GroupQ1 Stock

Read more
29 Apr 2019 15:46

Faron Gets Results Of Traumakine Study From Japanese Licensing Partner

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine for

Read more
11 Apr 2019 12:13

Faron Pharmaceuticals To Focus On Colorectal Cancer In Clevegen Trial

LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The testing of Clevegen on patients with will

Read more
11 Apr 2019 11:22

Faron Pharmaceuticals upbeat on latest info from MATINS trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 and 2 'MATINS' clinical trial, investigating the safety and efficacy of its wholly-owned novel precision cancer immunotherapy 'Clevegen', would begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing was determined.

Read more
26 Mar 2019 15:52

UPDATE: Faron Pharmaceuticals Raises EUR3.1 Million In Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday afternoon said it has raised EUR3.1 million pursuant to a placing announced earlier in the day.The company issued

Read more
26 Mar 2019 12:05

Faron Pharmaceuticals Optimistic For Traumakine As It Plans Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday said it expects further disappointing results from Traumakine, as it plans a share placing.Faron is currently for

Read more
21 Feb 2019 12:17

Faron "Very Encouraged" By Early Clevegen Trials In Cancer Patients

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said early results from a trial of its Clevegen cancer drug are encouraging.Shares in Faron were up 10% at 64.00 pence on said

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.